Premium Nahrungsergänzungsmittel | artgerecht

Macroalbuminuria: Causes, Symptoms and Treatment

Macroalbuminuria refers to a significantly elevated excretion of the protein albumin in the urine and is a key warning sign of severe kidney damage.

Regular tips about health Regular tips about health

Things worth knowing about "Macroalbuminuria"

Macroalbuminuria refers to a significantly elevated excretion of the protein albumin in the urine and is a key warning sign of severe kidney damage.

What is Macroalbuminuria?

Macroalbuminuria is a condition characterized by an abnormally high amount of the blood protein albumin being excreted in the urine. It is defined by a urinary albumin excretion of more than 300 mg per day, or an albumin-to-creatinine ratio (ACR) exceeding 300 mg/g in a spot urine sample. Macroalbuminuria represents an advanced stage of albuminuria and is considered a serious indicator of kidney damage.

Previously referred to as clinical proteinuria or overt nephropathy, macroalbuminuria marks a critical turning point in kidney disease progression. Beyond this threshold, the risk of kidney failure and cardiovascular complications increases significantly.

Causes

The most common causes of macroalbuminuria are chronic conditions that damage the kidney vessels and the glomeruli (the kidney's filtering units):

Diabetic nephropathy: Diabetes mellitus (both type 1 and type 2) is the leading cause. Chronically elevated blood glucose levels damage the small blood vessels within the kidneys.
Arterial hypertension: Persistently high blood pressure exerts excess pressure on the renal vessels, causing progressive damage.
Glomerulonephritis: Inflammatory diseases affecting the kidney filters can impair their filtering function over time.
Autoimmune diseases: Conditions such as systemic lupus erythematosus can directly affect kidney tissue.
Chronic kidney disease (CKD): Various underlying conditions can lead to macroalbuminuria over years of progression.

Symptoms

Macroalbuminuria itself often does not cause direct symptoms. However, when protein losses are very high, the following signs may appear:

Foamy urine: A visible sign of high levels of protein in the urine.
Edema: Fluid retention, particularly in the legs, feet, and around the eyes, caused by low protein levels in the blood.
Fatigue and weakness: A result of protein loss from the body.
High blood pressure: Often present simultaneously and accelerates kidney damage.

Because symptoms are frequently non-specific, macroalbuminuria is commonly detected through routine urine tests.

Diagnosis

Diagnosis is established through laboratory testing:

Urine analysis: Detection of albumin in the urine, typically via a 24-hour urine collection or the albumin-to-creatinine ratio (ACR) in a spot urine sample.
Threshold values: Macroalbuminuria is diagnosed when ACR exceeds 300 mg/g or albumin excretion exceeds 300 mg per 24 hours. For comparison, microalbuminuria falls between 30 and 300 mg/g.
Blood tests: Creatinine, urea, and glomerular filtration rate (GFR) are measured to assess kidney function.
Blood pressure monitoring and blood glucose control: Essential for identifying and managing underlying conditions.

Treatment

Treatment of macroalbuminuria aims to control the underlying disease and slow the progression of kidney damage:

Blood pressure control: ACE inhibitors or angiotensin II receptor blockers (ARBs) are the first-line treatment, as they also have a kidney-protective effect and reduce albumin excretion.
Blood glucose management: In diabetic patients, optimal glycemic control is essential to prevent further kidney damage.
Low-sodium diet: Helps reduce blood pressure and relieve strain on the kidneys.
Protein-restricted diet: May reduce kidney workload and slow disease progression.
SGLT2 inhibitors: Newer antidiabetic agents (e.g., empagliflozin, dapagliflozin) have demonstrated kidney-protective effects in chronic kidney disease.
Regular monitoring: Close follow-up of kidney function markers and blood pressure is essential.

References

Kidney Disease: Improving Global Outcomes (KDIGO) - KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International, 2022.
American Diabetes Association - Standards of Medical Care in Diabetes 2023. Diabetes Care, Volume 46, Supplement 1, 2023.
Brenner, B.M. (ed.) - Brenner and Rector's The Kidney, 11th edition. Elsevier, Philadelphia, 2020.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.